bluejay diagnostics inc - BJDX

BJDX

Close Chg Chg %
0.71 -0.01 -0.88%

Closed Market

0.70

-0.01 (0.88%)

Volume: 163.19K

Last Updated:

Dec 26, 2025, 4:00 PM EDT

Company Overview: bluejay diagnostics inc - BJDX

BJDX Key Data

Open

$0.69

Day Range

0.67 - 0.70

52 Week Range

0.65 - 10.20

Market Cap

$1.29M

Shares Outstanding

1.81M

Public Float

1.64M

Beta

0.61

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$32.24

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

141.72K

 

BJDX Performance

1 Week
 
-12.50%
 
1 Month
 
-46.15%
 
3 Months
 
-53.02%
 
1 Year
 
-80.66%
 
5 Years
 
N/A
 

BJDX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About bluejay diagnostics inc - BJDX

Bluejay Diagnostics, Inc. operates as a diagnostic company. It develops and markets minimally-invasive Point-of-Care diagnostics tests and devices that provide patients and providers with access to affordable and timely healthcare. It focus is on the infectious disease, inflammation, and oncology markets. The company was founded by Svetlana Dey and Dey Indraneil on March 20, 2015 and is headquartered in Acton, MA.

BJDX At a Glance

Bluejay Diagnostics, Inc.
360 Massachusetts Avenue
Acton, Massachusetts 01720
Phone 1-978-631-4884 Revenue 0.00
Industry Medical Specialties Net Income -7,717,794.00
Sector Health Technology Employees 7
Fiscal Year-end 12 / 2025
View SEC Filings

BJDX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 0.471
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.455
Enterprise Value to Sales N/A
Total Debt to Enterprise Value -0.074

BJDX Efficiency

Revenue/Employee N/A
Income Per Employee -1,102,542.00
Receivables Turnover N/A
Total Asset Turnover N/A

BJDX Liquidity

Current Ratio 6.045
Quick Ratio 6.045
Cash Ratio 5.309

BJDX Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -133.92
Return on Equity -178.977
Return on Total Capital -129.382
Return on Invested Capital -172.576

BJDX Capital Structure

Total Debt to Total Equity 4.112
Total Debt to Total Capital 3.95
Total Debt to Total Assets 3.539
Long-Term Debt to Equity 2.052
Long-Term Debt to Total Capital 1.971
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bluejay Diagnostics Inc - BJDX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - 249.04K
-
Sales Growth
- - - -100.00%
-
Cost of Goods Sold (COGS) incl D&A
145.72K 353.31K 780.96K 199.10K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
145.72K 306.37K 780.96K 199.10K
Depreciation
145.72K 306.37K 780.96K 199.10K
Amortization of Intangibles
- - - -
-
COGS Growth
-7.21% +142.46% +121.04% -74.51%
Gross Income
(145.72K) (104.27K) (780.96K) (199.10K)
Gross Income Growth
+7.21% +28.44% -648.95% +74.51%
Gross Profit Margin
- - - -41.87%
-
2021 2022 2023 2024 5-year trend
SG&A Expense
3.08M 9.21M 9.53M 6.97M
Research & Development
1.15M 4.15M 5.71M 3.47M
Other SG&A
1.94M 5.06M 3.82M 3.50M
SGA Growth
+196.77% +198.71% +3.44% -26.86%
Other Operating Expense
- - - -
-
Unusual Expense
- - (14.68K) 237.31K
-
EBIT after Unusual Expense
(3.22M) (9.56M) (10.31M) (7.17M)
Non Operating Income/Expense
94.65K 258.14K 357.33K 274.85K
Non-Operating Interest Income
- - 164.90K 145.82K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 367.46K 823.03K
-
Interest Expense Growth
- - - +1,261.11%
-
Gross Interest Expense
- - 367.46K 823.03K
-
Interest Capitalized
- - - -
-
Pretax Income
(3.49M) (9.30M) (9.95M) (7.72M)
Pretax Income Growth
-201.16% -166.52% -7.07% +22.46%
Pretax Margin
- - - -3,733.11%
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(3.49M) (9.30M) (9.95M) (7.72M)
Minority Interest Expense
- - - -
-
Net Income
(3.49M) (9.30M) (9.95M) (7.72M)
Net Income Growth
-201.16% -166.52% -7.07% +22.46%
Net Margin Growth
- - - -3,733.11%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(3.49M) (9.30M) (9.95M) (7.72M)
Preferred Dividends
- - - 13.22M
-
Net Income Available to Common
(3.49M) (9.30M) (9.95M) (20.94M)
EPS (Basic)
-1387.52 -3688.56 -3631.148 -114.1863
EPS (Basic) Growth
-90.09% -165.84% +1.56% +96.86%
Basic Shares Outstanding
2.51K 2.52K 2.74K 183.39K
EPS (Diluted)
-1387.52 -3688.56 -3631.148 -114.1863
EPS (Diluted) Growth
-90.09% -165.84% +1.56% +96.86%
Diluted Shares Outstanding
2.51K 2.52K 2.74K 183.39K
EBITDA
(3.08M) (9.01M) (9.53M) (6.97M)
EBITDA Growth
-196.77% -192.16% -5.76% +26.86%
EBITDA Margin
- - - -3,618.46%
-

Bluejay Diagnostics Inc in the News